Affiliations 

  • 1 School of Pharmacy, Department of Pharmaceutical Technology, International Medical University, Jalan Jalil Perkasa 19, 57000 Kuala Lumpur, Malaysia. Electronic address: rakeshtekade@gmail.com
  • 2 TIT College of Pharmacy, Technocrats Institute of Technology Campus, Anand Nagar, Raisen Road, Bhopal, MP 462021, India
  • 3 Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48201, USA
Drug Discov Today, 2016 Jul 2.
PMID: 27380716 DOI: 10.1016/j.drudis.2016.06.029

Abstract

The merger of nanotechnology and combination chemotherapy has shown notable promise in the therapy of resistant tumors. The latest scientific attention encompasses the engagement of anticancer drugs in combination with small interfering (si)RNAs, such as VEGF, XLAP, PGP, MRP-1, BCL-2 and cMyc, to name but a few. siRNAs have shown immense promise to knockout drug resistance genes as well as to recover the sensitivity of resistant tumors to anticancer therapy. The nanotechnology approach could also protect siRNA against RNAse degradation as well as prevent off-target effects. In this article, we discuss the approaches that have been used to deliver of siRNA in combination with chemotherapeutic drugs to treat resistant tumors. We also discuss the stipulations that must be considered in formulating a nanotechnology-assisted siRNA-drug cancer therapy.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.